Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation

Conclusion
Oral rivaroxaban appears to be an effective and safe alternative to VKAs and may allow prompt cardioversion.

Name of the trial registry
Clinicaltrials.gov; Trial registration number: NCT01674647.

Source: European Heart Journal - December 14, 2014 Category: Cardiology Authors: Cappato, R., Ezekowitz, M. D., Klein, A. L., Camm, A. J., Ma, C.-S., Le Heuzey, J.-Y., Talajic, M., Scanavacca, M., Vardas, P. E., Kirchhof, P., Hemmrich, M., Lanius, V., Meng, I. L., Wildgoose, P., van Eickels, M., Hohnloser, S. H., on behalf of the X-Ve Tags: ESC Hot Line Barcelona Source Type: research